Shares of Health Care sector company Moderna moved -1.1% today, and are now trading at a price of $24.34. The Mid-Cap stock's daily volume was 7,518,659 compared to its average volume of 10,350,814. The S&P 500 index returned a 1.0% performance.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company is based in Cambridge and has 5,800 full time employees. Its market capitalization is $9,468,255,232.
20 analysts are following Moderna and have set target prices ranging from $15.0 to $198.0 per share. On average, they have given the company a rating of hold. At today's prices, MRNA is trading -45.01% away from its average analyst target price of $44.25 per share.
Over the last year, MRNA shares have gone down by -62.6%, which represents a difference of -77.7% when compared to the S&P 500. The stock's 52 week high is $67.96 per share and its 52 week low is $23.15. Although Moderna's average free cash flow over the last 5 years has been $1.92 Billion, they have been decreasing at an average rate of -14.4%. For this reason, investors may continue to shun the stock.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2024 | -3,004,000 | 1,051,000 | -4,055,000 | -6.01 |
| 2023 | -3,118,000 | 707,000 | -3,825,000 | -183.5 |
| 2022 | 4,981,000 | 400,000 | 4,581,000 | -65.65 |
| 2021 | 13,620,000 | 284,000 | 13,336,000 | 580.76 |
| 2020 | 2,027,000 | 68,000 | 1,959,000 | 498.98 |
| 2019 | -459,000 | 32,000 | -491,000 |
